ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Operating Income

Last Annual Value

-75.25M

3-Year CAGR

-40%

5-Year CAGR

-133%

10-Year CAGR

-53%

ZB

Zura Bio Limited Competitors Analysis of Operating Income

ZURA · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
-75.25M
N/AN/AN/A 
-84.42M
N/AN/AN/A
-136.19M
N/AN/AN/A
-58.17M
N/AN/AN/A
-28.27M
N/AN/AN/A
-156.00M
N/AN/AN/A
-62.73M
N/AN/AN/A
-59.38M
N/AN/AN/A
-93.33M
N/AN/AN/A
-56.89M
N/AN/AN/A
-12.12M
N/AN/AN/A
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1